ClaimsBridge buys DialysisPPO, adds Eir backing
NEW YORK, UNITED STATES — ClaimsBridge announced two simultaneous transactions: a strategic equity investment from Eir Partners Capital and the acquisition of DialysisPPO, a patented cost containment specialist for end-stage renal disease (ESRD) and chronic dialysis treatment.
Both deals are designed to accelerate ClaimsBridge’s growth in the self-funded employer and commercial payer market.
Eir Partners backs ClaimsBridge at the pre-adjudication level
ClaimsBridge operates a claim and network technology platform centered on AI-enhanced pre-adjudication workflow, processing pricing and routing decisions before claims reach final adjudication.
Eir Partners Capital’s strategic investment provides the capital ClaimsBridge needs to scale that platform through both organic innovation and targeted acquisitions, with DialysisPPO representing the first.
“This is an important moment for ClaimsBridge. Eir’s investment gives us the ability to accelerate innovation for our clients and the payer market, and DialysisPPO is the strongest solution we’ve seen for one of healthcare’s most complex and expensive conditions,” said Kevin Gibson, chief executive officer at ClaimsBridge.
“Together, these moves reflect where we’re headed: simplifying complexity and taking cost out of the healthcare system,” Gibson added.
DialysisPPO’s ESRD savings expand the cost management suite
DialysisPPO’s program captures Medicare coordination of benefits savings for employers and payers treating ESRD patients, eliminating the standard 30-month waiting period to access those savings.
By joining the ClaimsBridge platform, DialysisPPO’s program reaches a substantially larger payer base, while those payers gain access to ClaimsBridge’s broader cost management suite alongside the dialysis solution.
“Joining ClaimsBridge allows us to bring our ESRD savings program to a much broader base of payers, backed by ClaimsBridge’s technology, network reach, and client service model. Just as important, our existing clients now gain access to a full suite of proven cost management solutions alongside the program they already rely on,” said John Brophy, chief executive officer and founder at DialysisPPO.
The double transaction structure reflects a growing pattern in healthcare business process outsourcing (BPO), where technology vendors use private equity investment to accelerate both organic product development and bolt-on acquisitions targeting specific high-cost conditions.
ESRD treatment is among the most expensive categories in health spending, and DialysisPPO’s program reduces per-member dialysis costs without requiring the 30-month Medicare coordination wait that limits most alternative approaches.
Brett Carlson, chief executive officer and founder of Eir Partners Capital, said the investment is about scaling ClaimsBridge’s platform faster, both organically and through acquisitions like DialysisPPO.
Related news
- Health Catalyst sells VitalWare for $147Mn · 12 Aug
- Nscale acquires Anyscale to build a full-stack AI cloud · 7 Aug
- CRC Advisors buys Aberdeenshire accountancy BBKS & Co · 10 Aug
Disclosure: Outsource Accelerator uses AI tools in the backend of its editorial workflow. Every article is reviewed and verified by a human editor before publication.
Stay ahead of the outsourcing industry. Join thousands of business leaders who rely on Outsource Accelerator for the news, trends, and expert insights that matter. Subscribe to our free newsletter and never miss an update.
